Conclusions
tumor, cholangiocarcinoma
TUMOR, ADVERSE EVENTS, SOLID TUMORS, MALIGNANCIES, MAY, CHOLANGIOCARCINOMA
Pemigatinib demonstrated manageable adverse events, consistent pharmacokinetics and pharmacodynamics profiles, and preliminary efficacy in Japanese patients with advanced solid tumors.FIGHT‐102 (NCT03235570) was an open‐label, phase 1 study of pemigatinib, a potent and selective inhibitor of FGFR1‐3, in Japanese patients with advanced solid malignancies. The safety, pharmacokinetics, and pharmacodynamic profiles of pemigatinib in this study are consistent with those reported in the phase 1 FIGHT‐101 and phase 2 FIGHT‐202 studies. No new safety signals were reported, and promising efficacy was observed with responses across tumor types including cholangiocarcinoma with 
[Correction added on May 13, 2023 after first online publication. The author name ‘Yukata’ has been corrected to ‘Yutaka’ in this version.]